Must be something I am missing. They have released a generic to earn less money than our original brand. There are other generics out there and the impact can be seen in the last quarters cash flows down 10 Million from last year due to the generics.
As a long term holder that sold when the patent came into dispute, I cant as yet see a reason to re-enter. They have no impending release of a new cash cow product and I havent noticed any updates for a while unless I missed one but still have the company on my watchlist. While the generic may assist in the drain of income cant see it healing it and a 25% increase in price seems overboard.
Happy to be proven wrong.
Add to My Watchlist
What is My Watchlist?
